A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival

Authors

Jacqueline S Garcia, Dana-Farber Cancer Institute
Ronan T Swords, AbbVie Inc.
Gail J Roboz, Cornell University
Meagan A Jacoby, Washington University School of Medicine in St. Louis
Guillermo Garcia-Manero, University of Texas MD Anderson Cancer Center
Wan-Jen Hong, Genentech Inc.
Xiaoqing Yang, AbbVie Inc.
Ying Zhou, AbbVie Inc.
Uwe Platzbecker, University of Leipzig
David P Steensma, Dana-Farber Cancer Institute
Johannes E Wolff, AbbVie Inc.
Pierre Fenaux, Université de Paris

Journal

Leukemia Research

Publication Date

5-1-2021

Volume

104

First Page

106555

Document Type

Open Access Publication

DOI

10.1016/j.leukres.2021.106555

Rights and Permissions

Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ, Yang X, Zhou Y, Platzbecker U, Steensma DP, Wolff JE, Fenaux P. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021 May;104:106555. doi: 10.1016/j.leukres.2021.106555. © 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Garcia, Jacqueline S; Swords, Ronan T; Roboz, Gail J; Jacoby, Meagan A; Garcia-Manero, Guillermo; Hong, Wan-Jen; Yang, Xiaoqing; Zhou, Ying; Platzbecker, Uwe; Steensma, David P; Wolff, Johannes E; and Fenaux, Pierre, "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival." Leukemia Research. 104, 106555 (2021).
https://digitalcommons.wustl.edu/oa_4/977

Additional Links

Supplemental material is available for this article at publisher site.